**MINUTES**

**CPIC CONFERENCE CALL**

DATE: April 5, 2012

PRESENT: Adriana Malheiro, Andrea Gaedigk, Daniel Mueller, Dina Paltoo, Grace Kuo, James Hoffman, Katrin Upsalla, Kevin Hicks, Mary Relling, Rachel Tyndale, Rochelle Long, Sam Johnson, Stuart Scott, Teri Klein

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Author involvement in CPIC guidelines | It was discussed that authors of CPIC guidelines should have expertise to contribute. Senior authors may of course hand-pick trainees to assist. CPIC guidelines will be highly scrutinized and must be able to stand up to criticisms. | Teri and Mary will clarify for authors that co-authors must make meaningful and high-quality contributions. |
| SLCO1B1/Statins, paper is in press | Alg Mary provided updates for Russ Wilke: that dosing algorithms have been implemented at Vanderbilt and at Duke (Voora/Ginsberg); Stuart Scott said they have plans. | If other groups are implementing SLCO1B1 genotyping, please let Russ know. |
| GTR brief update | Adriana indicated that the GTR is accepting submissions from labs doing pgen testing. First one listed in GTR is for ARUP and 2C19. | Rochelle will let PGRN members know that GTR is accepting submissions. |
| guidelines.gov brief update: | Rochelle and Marc Williams will work to get clopidogrel guideline in guidelines.gov format. It was discussed that CPIC did spend some time examining guidleines.gov formats before deciding on CPIC guideline format; the variety of formats used on guidelines.gov indicated that there was room to customize format of CPIC guidelines based on needs for pharmacogenetics guidelines, along with the special attribute that CPIC guidelines work from premise that test results are available. | Rochelle and Marc will let group know when drafts are available. |
| CPIC presentations | Rochelle discussed her preferences regarding CPIC presentations. Please let Rochelle, Mary, and Teri know beforehand if you will present on CPIC and what you will be saying. There is some responsibility for maintaining accuracy and quality of information about CPIC, the PGRN, and PharmGKB. There are now logos for CPIC; it is on PharmGKB and will be added to pgrn.org site. | CPIC members should let Rochelle, Mary, and Teri know about presentations on CPIC; those who use the logos for PGRN and CPIC will note the permission statements associated with their download. |
| NHGRI’s G2C2 efforts on pharmacogenomics competencies and dissemination plans | Grace Kuo discussed NHGRI conference in December with pharmacy organizations discussing competencies, and there is interest in referencing CPIC from G2C2 site. Matthias Schwab noted that working with European Pharmacogenetic Education Network could be useful. | Grace, Teri, and Rochelle will suggest next steps for further working with education groups on establishing professional pharmacogenetic competencies |
| TCA guideline issues | Kevin & Teri discussed issues specific to the TCA guideline: involvement of > 1 gene and up to 7 TCAs, multiple diseases, along with a paucity of clinical outcome but a plethora of PK data, is complicating writing the CPIC guideline. Consensus was to focus on a Table 2 with at least one “strong” recommendation (e.g. amitriptyline dosing, 2C19 and 2D6 genotype, and depression as the disease)—with footnotes and references to text and supplement to handle (a) drugs with less data and thus weaker recommendations (b) other diseases and (c) less clear roles for 2C19.  Also, the need to share multiple documents, for the very thorough review of data for this guideline, is being addressed with help from Teri and PharmGKB staff. | Kevin will communicate discussion to entire TCA writing group and draft new tables.  Teri established “drop box” for documents. |